Final data from long-term study of CombiGene’s epilepsy treatment indicate clearly positive effects in the form of fewer and shorter seizures.

Feb 19, 2018

Final data from CombiGene’s preclinical proof-of-concept-study (the long-term study) show that CombiGene’s candidate drug, CG01, has clear antiepileptic effects. The study has demonstrated that CG01 reduces the frequency and duration of epileptic seizures in treatment-responsive animals. A couple of the animals were completely free of seizures after being treated. No side effects have been observed in the study.